巴替非班在急性冠脉综合征患者经皮冠状动脉介入治疗中的应用价值

目的探讨巴替非班在非ST段抬高型急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗中应用的临床疗效。方法择期行经皮冠状动脉介入术的ACS患者66例,随机分为巴替非班组(n=34)和安慰剂组(n=32),其中巴替非班组脱落/剔除5例,安慰剂组脱落/剔除8例。2组术中及术后24 h分别采用巴替非班或安慰剂治疗。观察2组术后慢血流发生率与支架植入后冠脉血流TIMI分级。观察2组术后2 d、30 d内心血管事件(MACE)发生情况。结果 2组患者基线资料相当(P>0.05),术后均未发生即刻慢血流事件,TIMI分级均为3级,2组比较差异无统计学意义(P>0.05)。2组在术后2 d、30 d内均无MACE事件发生。2组术后2d内出血事件、不良反应比较无统计学差异(P>0.05)。结论巴替非班在非ST段抬高型ACS患者经皮冠状动脉介入术中及术后应用,疗效肯定,安全性好。

The effects of batifiban during percutaneous coronary intervention in acute coronary syndrome patients

Objective To observe the clinical effect and safety of batifiban in non-ST segment elevation acute coronary syndrome（ACS）patients who received percutaneous coronary intervention（PCI）.Methods A total of 66 non-ST segment elevation ACS patients receiving PCI were included and randomized into batifiban group（n=34）and placebo group （n=32）.There were 5 and 8 missing/excluded patients in group batifiban and placebo,respectively.The major adverse cardiac events（MACE）include refractory ischemia,new myocardial infarction and death,cerebral apoplexy and hemorrhage complication were observed.Results The baseline data of the two groups were not significantly different（P 0.05）.The MACE at 30 days was not significantly different between two groups（P 0.05）.There were no differences in the incidence of bleeding or platelet decrease between two groups.There was no coronary slow flow phenomenon in two groups.Conclusion Compared with placebo group,using batifiban in non-ST segment elevation ACS patients is safe and effect during PCI procedures.